{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:29:02Z","timestamp":1789770542152,"version":"4.0.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T00:00:00Z","timestamp":1677456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.ajo.2022.11.026","type":"journal-article","created":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T02:16:20Z","timestamp":1670465780000},"page":"108-125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Safety of Lenadogene Nolparvovec Gene Therapy Over 5 Years in 189 Patients With Leber Hereditary Optic Neuropathy"],"prefix":"10.1016","volume":"249","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0292-8905","authenticated-orcid":false,"given":"CATHERINE","family":"VIGNAL-CLERMONT","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7847-9320","authenticated-orcid":false,"given":"PATRICK","family":"YU-WAI-MAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NANCY J.","family":"NEWMAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4923-6404","authenticated-orcid":false,"given":"VALERIO","family":"CARELLI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0525-1488","authenticated-orcid":false,"given":"MARK L.","family":"MOSTER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"VALERIE","family":"BIOUSSE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5824-8322","authenticated-orcid":false,"given":"PREM S.","family":"SUBRAMANIAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AN-GUOR","family":"WANG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SEAN P.","family":"DONAHUE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BART P.","family":"LEROY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ALFREDO A.","family":"SADUN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2805-4652","authenticated-orcid":false,"given":"THOMAS","family":"KLOPSTOCK","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ROBERT C.","family":"SERGOTT","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GEMA","family":"REBOLLEDA\u00a0FERNANDEZ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BART K.","family":"CHWALISZ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RUDRANI","family":"BANIK","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1139-5178","authenticated-orcid":false,"given":"MAGALI","family":"TAIEL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MICHEL","family":"ROUX","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JOS\u00c9-ALAIN","family":"SAHEL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ajo.2022.11.026_bib0001","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s00401-016-1625-2","article-title":"A neurodegenerative perspective on mitochondrial optic neuropathies","volume":"132","author":"Yu-Wai-Man","year":"2016","journal-title":"Acta Neuropathol (Berl)"},{"issue":"5","key":"10.1016\/j.ajo.2022.11.026_bib0002","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.bbabio.2009.02.024","article-title":"Retinal ganglion cell neurodegeneration in mitochondrial inherited disorders","volume":"1787","author":"Carelli","year":"2009","journal-title":"Biochim Biophys Acta BBA - Bioenerg"},{"key":"10.1016\/j.ajo.2022.11.026_bib0003","article-title":"Understanding the molecular basis and pathogenesis of hereditary optic neuropathies: towards improved diagnosis and management","author":"Newman","year":"2022","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.ajo.2022.11.026_bib0004","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/WNO.0000000000000570","article-title":"International consensus statement on the clinical and therapeutic management of Leber hereditary optic neuropathy","volume":"37","author":"Carelli","year":"2017","journal-title":"J Neuroophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2022.11.026_bib0005","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/WNO.0000000000001045","article-title":"Visual outcomes in Leber hereditary optic neuropathy patients with the m.11778G>A (MTND4) mitochondrial DNA mutation","volume":"40","author":"Newman","year":"2020","journal-title":"J Neuroophthalmol"},{"key":"10.1016\/j.ajo.2022.11.026_bib0006","unstructured":"EMA. Raxone. European Medicines Agency. Published September 17, 2018. Accessed April 22, 2022. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/raxone."},{"issue":"Pt 9","key":"10.1016\/j.ajo.2022.11.026_bib0007","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1093\/brain\/awr170","article-title":"A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy","volume":"134","author":"Klopstock","year":"2011","journal-title":"Brain J Neurol"},{"issue":"573","key":"10.1016\/j.ajo.2022.11.026_bib0008","doi-asserted-by":"crossref","first-page":"eaaz7423","DOI":"10.1126\/scitranslmed.aaz7423","article-title":"Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathy","volume":"12","author":"Yu-Wai-Man","year":"2020","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.ajo.2022.11.026_bib0009","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.ophtha.2020.12.012","article-title":"Efficacy and safety of intravitreal gene therapy for Leber hereditary optic neuropathy treated within 6 months of disease onset","volume":"128","author":"Newman","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2022.11.026_bib0010","first-page":"21587","article-title":"Efficacy and safety of rAAV2-ND4 treatment for Leber's hereditary optic neuropathy","volume":"6","author":"Wan","year":"2016"},{"key":"10.1016\/j.ajo.2022.11.026_bib0011","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ebiom.2016.07.002","article-title":"Long-term outcomes of gene therapy for the treatment of Leber's hereditary optic neuropathy","volume":"10","author":"Yang","year":"2016","journal-title":"EBioMed"},{"issue":"8","key":"10.1016\/j.ajo.2022.11.026_bib0012","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.ophtha.2020.02.023","article-title":"Seven-year follow-up of gene therapy for Leber's hereditary optic neuropathy","volume":"127","author":"Yuan","year":"2020","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ajo.2022.11.026_bib0013","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ophtha.2015.10.025","article-title":"Gene therapy for Leber hereditary optic neuropathy: initial results","volume":"123","author":"Feuer","year":"2016","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1016\/j.ajo.2022.11.026_bib0014","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/j.ophtha.2017.05.016","article-title":"Gene therapy for Leber hereditary optic neuropathy: low- and medium-dose visual results","volume":"124","author":"Guy","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2022.11.026_bib0015","article-title":"Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy","author":"Newman","year":"2022","journal-title":"Brain"},{"key":"10.1016\/j.ajo.2022.11.026_bib0016","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0076-6879(96)64035-X","article-title":"Allotopic expression of mitochondrial ATP synthase genes in nucleus of Saccharomyces cerevisiae","volume":"264","author":"Gray","year":"1996","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.ajo.2022.11.026_bib0017","doi-asserted-by":"crossref","first-page":"15003","DOI":"10.1038\/mtm.2015.3","article-title":"Nuclear expression of mitochondrial ND4 leads to the protein assembling in complex I and prevents optic atrophy and visual loss","volume":"2","author":"Cwerman-Thibault","year":"2015","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"6","key":"10.1016\/j.ajo.2022.11.026_bib0018","doi-asserted-by":"crossref","first-page":"e730","DOI":"10.1111\/aos.14379","article-title":"Factors associated with rapid improvement in visual acuity in patients with Leber's hereditary optic neuropathy after gene therapy","volume":"98","author":"Liu","year":"2020","journal-title":"Acta Ophthalmol (Copenh)"},{"issue":"4","key":"10.1016\/j.ajo.2022.11.026_bib0019","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1001\/jamaophthalmol.2018.6902","article-title":"Immune response and intraocular inflammation in patients with Leber hereditary optic neuropathy treated with intravitreal injection of recombinant adeno-associated virus 2 carrying the ND4 gene","volume":"137","author":"Bouquet","year":"2019","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2022.11.026_bib0020","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40259-021-00468-9","article-title":"Safety of intravitreal gene therapy for treatment of subjects with Leber hereditary optic neuropathy due to mutations in the mitochondrial ND4 gene: the REVEAL study","volume":"35","author":"Vignal-Clermont","year":"2021","journal-title":"Biodrugs"},{"key":"10.1016\/j.ajo.2022.11.026_bib0021","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.662838","article-title":"Intravitreal gene therapy vs. natural history in patients with Leber hereditary optic neuropathy carrying the m.11778G>A ND4 mutation: systematic review and indirect comparison","volume":"12","author":"Newman","year":"2021","journal-title":"Front Neurol"},{"issue":"3","key":"10.1016\/j.ajo.2022.11.026_bib0022","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/WNO.0000000000001367","article-title":"Long-term follow-up after unilateral intravitreal gene therapy for Leber hereditary optic neuropathy: the RESTORE study","volume":"41","author":"Biousse","year":"2021","journal-title":"J Neuroophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2022.11.026_bib0023","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2022.11.026_bib0024","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0161-6420(85)34001-0","article-title":"Standardization of vitreal inflammatory activity in intermediate and posterior uveitis","volume":"92","author":"Nussenblatt","year":"1985","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ajo.2022.11.026_bib0025","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1136\/jnnp.59.2.160","article-title":"Leber's \u201cplus\u201d: neurological abnormalities in patients with Leber's hereditary optic neuropathy","volume":"59","author":"Nikoskelainen","year":"1995","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.ajo.2022.11.026_bib0026","author":"Hage","year":"2019","journal-title":"Neurological findings in patients with Leber's hereditary optic neuropathy - NANOS Annual Meeting"},{"key":"10.1016\/j.ajo.2022.11.026_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102071","article-title":"Optic nerve atrophy and whole and regional brain atrophy in Leber's hereditary optic neuropathy with multiple sclerosis-like disease with m.11778G>A mutation","volume":"42","author":"Ro\u015bciszewska-\u017bukowska","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"10.1016\/j.ajo.2022.11.026_bib0028","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s12883-022-02787-y","article-title":"Absence of lenadogene nolparvovec DNA in a brain tumor biopsy from a patient in the REVERSE clinical study, a case report","volume":"22","author":"Newman","year":"2022","journal-title":"BMC Neurol"},{"issue":"10097","key":"10.1016\/j.ajo.2022.11.026_bib0029","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet Lond Engl"},{"issue":"21","key":"10.1016\/j.ajo.2022.11.026_bib0030","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1056\/NEJMoa0802315","article-title":"Safety and efficacy of gene transfer for Leber's congenital amaurosis","volume":"358","author":"Maguire","year":"2008","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ajo.2022.11.026_bib0031","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s41591-020-0763-1","article-title":"Initial results from a first-in-human gene therapy trial on X-linked retinitis pigmentosa caused by mutations in RPGR","volume":"26","author":"Cehajic-Kapetanovic","year":"2020","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.ajo.2022.11.026_bib0032","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1016\/j.ymthe.2018.05.025","article-title":"Retinal AAV8-RS1 gene therapy for X-linked retinoschisis: initial findings from a phase I\/IIa trial by intravitreal delivery","volume":"26","author":"Cukras","year":"2018","journal-title":"Mol Ther"},{"issue":"4","key":"10.1016\/j.ajo.2022.11.026_bib0033","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1167\/tvst.10.4.3","article-title":"Inflammation in viral vector-mediated ocular gene therapy: a review and report from a workshop hosted by the foundation fighting blindness, 9\/2020","volume":"10","author":"Chan","year":"2021","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.ajo.2022.11.026_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2022.02.023","article-title":"Leber hereditary optic neuropathy gene therapy: adverse events and visual acuity results of all patient groups","author":"Lam","year":"2022","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2022.11.026_bib0035","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1001\/jamaophthalmol.2013.7630","article-title":"Safety and effects of the vector for the Leber hereditary optic neuropathy gene therapy clinical trial","volume":"132","author":"Koilkonda","year":"2014","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2022.11.026_bib0036","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/mt.2010.258","article-title":"Preclinical safety evaluation of AAV2-sFLT01\u2014 a gene therapy for age-related macular degeneration","volume":"19","author":"MacLachlan","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.ajo.2022.11.026_bib0037","article-title":"Safety and biodistribution evaluation in cynomolgus macaques of rAAV2tYF-CB-hRS1, a recombinant adeno-associated virus vector expressing retinoschisin","author":"Ye","year":"2015","journal-title":"Hum Gene Ther Clin Dev"},{"issue":"2","key":"10.1016\/j.ajo.2022.11.026_bib0038","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1089\/hum.2016.111","article-title":"Evaluation of dose and safety of AAV7m8 and AAV8BP2 in the non-human primate retina","volume":"28","author":"Ramachandran","year":"2017","journal-title":"Hum Gene Ther"},{"issue":"1-2","key":"10.1016\/j.ajo.2022.11.026_bib0039","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1089\/hum.2019.144","article-title":"Ocular inflammatory response to intravitreal injection of adeno-associated virus vector: relative contribution of genome and capsid","volume":"31","author":"Timmers","year":"2020","journal-title":"Hum Gene Ther"},{"issue":"4","key":"10.1016\/j.ajo.2022.11.026_bib0040","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s40123-020-00287-1","article-title":"Treatment-emergent adverse events in gene therapy trials for inherited retinal diseases: a narrative review","volume":"9","author":"Nuzbrokh","year":"2020","journal-title":"Ophthalmol Ther"},{"issue":"5","key":"10.1016\/j.ajo.2022.11.026_bib0041","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1097\/00006982-200410000-00002","article-title":"Risks of intravitreous injection: a comprehensive review","volume":"24","author":"Jager","year":"2004","journal-title":"Retina"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939422004640?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939422004640?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T13:52:59Z","timestamp":1757598779000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939422004640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":41,"alternative-id":["S0002939422004640"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2022.11.026","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of Lenadogene Nolparvovec Gene Therapy Over 5 Years in 189 Patients With Leber Hereditary Optic Neuropathy","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2022.11.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}